Several other brokerages also recently issued reports on FME. Stifel Nicolaus set a €60.00 ($64.52) price target on Fresenius Medical Care AG & Co. KGaA in a report on Friday, February 4th. Credit Suisse Group set a €61.00 ($65.59) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, February 28th. JPMorgan Chase & Co. set a €48.70 ($52.37) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday. The Goldman Sachs Group set a €71.00 ($76.34) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, March 22nd. Finally, Jefferies Financial Group set a €53.00 ($56.99) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, February 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and an average price target of €65.47 ($70.40).
Shares of ETR FME opened at €59.44 ($63.91) on Friday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €50.98 ($54.82) and a 12-month high of €71.14 ($76.49). The company has a market cap of $17.42 billion and a P/E ratio of 17.96. The company has a current ratio of 1.10, a quick ratio of 0.76 and a debt-to-equity ratio of 95.29. The stock has a fifty day moving average price of €59.67 and a 200 day moving average price of €58.60.
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.